Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.
The purpose of this study is to find the highest dose of the investigational drug glofitamab that can be given safely alone or with obinutuzumab in patients with non-Hodgkin lymphoma that came back or continued to grow despite treatment. Glofitamab is a "bispecific antibody" that binds to two different proteins: one found on the surface of cancer cells and one found on the surface of immune cells. Researchers think that glofitamab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Both drugs are given intravenously (by vein).
Bacillus Calmette Guerin (BCG) is standard therapy for people with bladder cancer that has not grown into the muscle wall. It is given intravesically (directly into the bladder) and stimulates the immune system to kill cancer cells. But sometimes the cancer comes back.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
Researchers in this study want to see how a new form of radiation therapy works to treat metastatic cancer. Metastatic means the cancer has spread to another part of the body from its original place. The people in this study have solid tumors that spread to soft tissues in the chest, abdomen (belly), or pelvis. In addition, they need radiation therapy to help control symptoms such as pain.
ARV-806 is designed to help get rid of bad or unwanted proteins. It breaks down the KRAS protein in cancer cells, which plays a role in cancer growth and survival. By targeting this protein, ARV-806 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Researchers want to find the best dose of the antibody-drug conjugate LY4101174 to treat advanced bladder and prostate cancers. The people in this study have bladder or prostate cancer that came back or keeps growing after treatment. 
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
